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Abstract
Purpose: UK primary care provides a rich data source for research. The impact of
proposed data collection restrictions is unknown. This study aimed to assess the
impact of restricting the scope of electronic health record (EHR) data collection on
the ability to conduct research. The study estimated the consequences of restricted
data collection on published Clinical Practice Research Datalink studies from high
impact journals or referenced in clinical guidelines.
Methods: A structured form was used to systematically analyse the extent to
which individual studies would have been possible using a database with data collec-
tion restrictions in place: (1) retrospective collection of specified diseases only; (2)
retrospective collection restricted to a 6‐ or 12‐year period; (3) prospective and
retrospective collection restricted to non‐sensitive data. Outcomes were categorised
as unfeasible (not reproducible without major bias); compromised (feasible with
design modification); or unaffected.
Results: Overall, 91% studies were compromised with all restrictions in place; 56%
studies were unfeasible even with design modification. With restrictions on diseases
alone, 74% studies were compromised; 51% were unfeasible. Restricting collection to
6/12 years had a major impact, with 67 and 22% of studies compromised, respec-
tively. Restricting collection of sensitive data had a lesser but marked impact with
10% studies compromised.
Conclusion: EHR data collection restrictions can profoundly reduce the capacity for
public health research that underpins evidence‐based medicine and clinical guidance.
National initiatives seeking to collect EHRs should consider the implications of
restricting data collection on the ability to address vital public health questions.
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1 | INTRODUCTION
It is well established that unrepresentative patient populations or
missing data can pose significant obstacles when conducting public
health research.1-5 The scope and quality of national electronic health
record (EHR) data sources that are accessible for research purposes
varies significantly between countries, depending on the health care
system and primary reason for collection. As a universal health care
provider, free at the point of delivery, the UK National Health Service
(NHS) encompasses over 90% of the UK population. The UK primary
care EHR contains demographic, diagnostic, treatment, referral, and
lifestyle information, thus creating a continuous record of an individ-
ual's health and medical care throughout their lifetime. Consequently,
UK primary care data provide a rich source of longitudinal, compre-
hensive health care data for public health research.
Several databases exist that enable research access to anonymised
EHR data, collected from a subset of the total UK primary care general
practices (GPs).6-8 A recent analysis evaluating the publication output
from the three largest primary care EHR databases in the United King-
dom showed close to a 20% annual growth rate, rising from seven
publications in 1995 to 171 throughout 2015.9 Moreover, approxi-
mately 30% of research conducted using UK primary care databases
is by international institutions, including research groups from the
United States, Canada, Australia, and Europe.9 The Clinical Practice
Research Datalink (CPRD), supported by the Medicines and
Healthcare products Regulatory Agency and National Institute of
Health Research, is a UK government research service that has been
providing anonymised UK primary care data for public health studies
since the late 1980s.6 CPRD data are used extensively by academics,
regulators, and the pharmaceutical industry worldwide to investigate
drug and vaccine safety,10-17 assess uptake and effectiveness of public
health policy and clinical guidance,18-23 characterise the prevalence of
diseases and associated risk factors,24 and improve health care deliv-
ery.25-28 Twenty‐five National Institute for Health and Clinical Excel-
lence (NICE) guidance documents covering 12 disease areas have
used CPRD data, including recommendations for suspected cancer
referrals that drew exclusively on studies using CPRD data.29
The accuracy and generalisability of research using CPRD data is
underpinned by the population level coverage of the NHS, the longitu-
dinal nature of the database, and the quality of the CPRD data made
available for research: EHR data from a total of 22 million patients
across the United Kingdom from 1987 onwards are available for public
health studies. The composition of the dataset aligns with the overall
UK population with respect to age and sex.6 To provide more informa-
tion about patient care pathways and disease management across
multiple settings, CPRD data are linked to other health care data
sources, including inpatient and outpatient hospital care data.30
Longitudinal data enable simultaneous retrospective and prospec-
tive analyses31 and are invaluable when there is insufficient time to
carry out a randomised clinical trial in response to safety concerns.
In 2014, near real‐time data were used to evaluate the safety of a
new national pertussis immunisation programme for pregnant women,
introduced to combat an outbreak of whooping cough in newborns.11
Initial results from observational studies using UK EHRs were available
within 6 months, a time frame that would be impractical for
randomised clinical trials to generate results.11
The NHS England programme, care.data, initiated in 2013 and
closed in 2016, sought to capture health care data from all general
practices in England.32 Data were to be collected by the national
Health and Social Care Information Centre (HSCIC), now known as
NHS Digital and made available by HSCIC for the secondary purposes
of commissioning, service planning, and research.
A set of limitations on data collection were proposed during devel-
opment of the programme:
1. Restricting the retrospective collection of data to specified dis-
eases, risk factors, and conditions defined by Read codes (Table
S2). Specified disease areas primarily covered cardiovascular dis-
ease, diabetes, respiratory disease, mental health, cancer, and neu-
rodegenerative disease.
2. Restricting retrospective data collection to either 6 years (pro-
posed to begin in 2016, ie, 2010 onwards for the purpose of
this study) or 12 years (2004 onwards) (time‐limited retrospec-
tive data)
3. Restricting the prospective and retrospective collection of sensi-
tive data; the exclusion of legally restricted or particularly sensitive
data, eg, in vitro fertilisation, abortion, gender reassignment, sexu-
ally transmitted infections, and HIV status (Table S3).
The impact of such restrictions on the output of public health
research is not known.
This study aims to systematically review the potential impact of
restricting the scope of EHR data on observational and
pharmacovigilance research outcomes in accordance with proposed
care.data programme data limitations of time, sensitive data, and spe-
cific diseases, using the CPRD database as an exemplar.
KEY POINTS
• UK primary care provides a rich source of data for public
health research, but the impact of government‐proposed
restrictions on data collection has not previously been
studied.
• This study analysed the extent to which high‐impact
studies would have been possible using a database with
data collection restrictions in place.
• Overall, 91% of studies were deemed compromised if
repeated with all restrictions in place, and 56% of
studies were unfeasible even with design modification.
• Findings from this study can be widely used to promote
better understanding of the patient and public health
benefits of data sharing.
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2 | METHODS
The consequences of the proposed restrictions on observational
research were modelled by examining the feasibility of repeating
previously conducted CPRD studies under a restricted data collec-
tion model.
2.1 | Search strategy
Published, high‐impact, observational research studies conducted
using anonymised, longitudinal primary care data from CPRD and from
its predecessor the General Practice Research Database (GPRD) were
identified for review using a systematic approach (Figure 1).
High‐impact research was defined as being referenced in a UK clin-
ical guidance document and/or published in a top five journal accord-
ing to impact factor for the relevant field of study, (a) Pharmacology
and Pharmacy (b) Medicine, General, and Internal, and (c) Public Envi-
ronmental and Occupational Health (Table S1). Impact factors were
identified through the Journal Citation Reports database on the ISI
Web of Knowledge platform.33
Studies referenced in UK clinical guidance documents were identified
from a recent systematic review.34 Studies published in a top five journal
were identified by searching the CPRD bibliography, which is compiled
through systematic searches of PubMed (https://www.ncbi.nlm.nih.
gov/pubmed) using the term (“CPRD”) OR (“clinical practice research
datalink”) OR (“GPRD”) OR (“general practice research database”).
2.2 | Eligibility criteria
Studies were included if they were referenced in a clinical guidance doc-
ument or had been published in a high‐impact journal on or before 20
July 2015 and used CPRD or GPRD data. Studies were excluded if they
were published in a language other than English, did not include any pri-
mary research, or were not an original report/full journal article. This
excluded reviews, meta‐analyses, editorials, letters, commentaries, and
research letters. Publications on interventional studies were also
excluded. No restrictions were imposed on the period covered by the
respective publication, and the methodological quality of studies was
not considered as part of the eligibility criteria for inclusion in the review.
Eligibility for inclusion in the study was ascertained by indepen-
dent review of published abstracts by at least two researchers. Dupli-
cate and related publications were flagged and removed. A sample of
100 publications from the total eligible pool was selected for review
and data extraction. Publications were sampled with priority given to
the most recently published manuscripts. Sampling effectively added
a time criterion to the review so that only studies published on or after
January 2000 were included.
2.3 | Assessing the impact of restrictions
The impact of restricting data collection on study feasibility and inter-
nal validity was evaluated using the questionnaire shown in Box 2. For
each publication, two researchers independently assessed full texts of
eligible manuscripts using the questionnaire to determine whether the
study could be repeated under the restriction scenarios outlined.
Researchers assumed a study start date of 2016, in line with the pro-
posed care.data launch date. The impact of restricting retrospective
data collection to a limited time period was considered from two per-
spectives: (a) the impact of restricted data collection over a fixed
length of time, ie, either 6 or 12 years of historical data and (b) over
a restricted calendar period, ie, not having events recorded before
either 01/01/2010 or 01/01/2004 (Table 3).
The questionnaire was initially piloted by five researchers to assess
internal consistency and completeness of capture. Discordance
between reviewers at the development stage and data abstraction
stage was resolved with discussion or by a third reviewer when a con-
sensus could not be reached.
Outcomes were categorised as either unfeasible, ie, not able to be
reproduced without the introduction of major bias (eg, selection bias,
detection bias, and misclassification); compromised, ie, feasible but
requiring study design modification; or unaffected, ie, no impact of
the restrictions. No assessment of publication bias was performed.FIGURE 1 Flow diagram of manuscript identification
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Box 1. Questionnaire
Study information
1. Publication reference no.
2. Lead author
3. Year of publication
4. Title of publication
5. Study type—Select one of following options only:
Adverse drug reaction/drug safety, drug utilisation,
disease epidemiology, drug effectiveness,
pharmacoeconomics, methodological, health/public
health services research, other
6. Multi‐database study? (Select one of the following
options: Y—other non‐linked UK database, Y—other
foreign database, Y—other non‐linked UK database
and other foreign database, N) If Y, list databases
7. Linked data sources (Y, N) If Y, tick all that apply: ONS
mortality, HES APC, HES OP, CR, SES‐practice, SES‐
patient, MINAP, other/bespoke linkage
8. Study population or denominator population (ie, all
adults over age 18 years)
a. Select one category (Supplementary Table AAA) that
best describes the study population/denominator
b. Describe study population/denominator including
important inclusion and exclusion criteria, time
periods, and any other important details
9. Primary study exposure (ie, smoking), if appropriate
a. Select one category (Supplementary Table AAA) of
exposure
b. Describe exposure
10. Primary study outcome (ie, lung cancer), if appropriate
a. Select one category (Supplementary Table AAA) of
outcome
b. Describe outcome
11. Important covariates/confounders (defined as covariates/
confounders mentioned in introduction or discussion of
paper), if applicable. List covariates/confounders
12. Key findings (Copy results and conclusions directly
from publication abstract)
Feasibility and bias assessment
Restricting sensitive data
With retrospective and prospective restricted to nonsensitive
data, would it be possible to fully define the following, where
fully defined means “as defined in the CPRD study”?
1. Study population/denominator: (Select one of: Y, N—
because definition includes legally restricted codes, N
—because definition includes abortion and gender
codes, N—because definition includes other sensitive
codes, n/a)
If N, provide additional details, for example whether
codes used as inclusion or exclusion criteria
2. Primary exposure: (Select one of: Y, N—because
definition includes legally restricted codes, N—because
definition includes abortion and gender codes, N—
because definition includes other sensitive codes, n/a)
3. Primary outcome: (Select one of: Y, N—because
definition includes legally restricted codes, N—because
definition includes abortion and gender codes, N—
because definition includes other sensitive codes, n/a)
4. Important covariates/confounders—select N if the
answer for any of the covariates/confounders is N:
(Select one of: Y, N—because definition includes
legally restricted codes, N—because definition includes
abortion and gender codes, N—because definition
includes other sensitive codes, n/a)
If N, list variables
If N to any of Q1‐Q4, could the study objectives have been
met, without major bias, if the definition of the following
were changed?
5. Study population/denominator: (Select one of: Y—
change the definition in primary care, Y—change
definition by adding/using linked HES/ONS data
(assuming no restrictions of sensitive date), N, n/a)
6. Primary exposure: (Select one of: Y—change the
definition in primary care, Y—change definition by
adding/using linked HES/ONS data (assuming no
restrictions of sensitive date), N, n/a)
7. Primary outcome: (Select one of: Y—change the
definition in primary care, Y—change definition by
adding/using linked HES/ONS data (assuming no
restrictions of sensitive date), N, n/a)
8. Important covariates/confounders—select N if the
answer for any of the covariates/confounders is N:
(Select one of: Y—change the definition in primary
care, Y—change definition by adding/using linked
HES/ONS date (assuming no restrictions of sensitive
date), N, n/a)
Excluding historical data prior to 2010
In answering these questions, assume that there would be
full coded historic data. The aspect of incomplete/limited
historic data capture for specific conditions, risk factors,
etc is assessed in Q7 and Q8. All the questions below
should be answered as if the CPRD study were to be
conducted on January 1, 2016, using only 6 years of
historic, retrospective data.
9. Restricting historic information to events recorded
on or after to 01/01/2010, what would be the
impact of replicating the study using only 5 years
of follow‐up (mark all that apply)?
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3 | RESULTS
Figure 1 shows the process of identification of manuscripts eligible for
inclusion. From a total pool of 1391 studies, 111 publications were
identified by impact factor criteria, and 25 were identified by a
recently published systematic review of studies using CPRD or GPRD
data that were subsequently included in UK clinical guidelines.29 Fol-
lowing removal of duplicates, 131 unique manuscript abstracts were
reviewed for eligibility, of which 119 manuscripts met the full
inclusion/exclusion criteria and were eligible for full review. Full
review further identified four ineligible manuscripts. Due to resourcing
restraints, a sample of 100 publications from the total eligible pool of
a. No impact
b. Bias could be introduced (eg, bias due to
misclassification)
c. The likelihood of ascertaining the association
between exposure and outcome would be limited
because of lag between first exposure and
outcome ascertainment (eg, drug exposure and
cancer outcome)
d. The ability to explore temporal trends would be
limited
e. Study would be unfeasible
10. Restricting historic information to events recorded on or
after to 01/01/2010, what would be the impact of not
having data prior to 2010 (mark all that apply)?
a. None
b. Study not feasible because exposure/outcome not
available after 2010
c. Study not feasible because event of interest (eg,
guideline released) occurred prior to 2010
d. Study not feasible for other reason(s)
Excluding historical data prior to 2004
In answering these questions, assume that there would be
full coded historic data. The aspect of incomplete/limited
historic data capture for specific conditions, risk factors,
etc is assessed in Q7 and Q8. All the questions below
should be answered as if the CPRD study were to be
conducted on January 1, 2016, using only 12 years of
historic, retrospective data.
11. Restricting historic information to events recorded on
or after 01/01/2004, what would be the impact of
replicating the study using only 11 years of follow‐up
(mark all that apply)?
a. None
b. Bias could be introduced (eg, due to misclassification)
c. The likelihood of ascertaining the association
between exposure and outcome would be limited
because of lag between first exposure and
outcome ascertainment (eg, drug exposure and
cancer outcome)
d. The ability to explore temporal trends would be
limited
e. Study would be unfeasible
12. Restricting historic information to events recorded on
or after to 01/01/2004, what would be the impact of
not having data prior to 2004 (mark all that apply)?
a. None
b. Study not feasible because exposure/outcome not
available after 2004
c. Study not feasible because event of interest (eg,
guideline released) occurred prior to 2004
d. Study not feasible for other reason(s)
Limiting historical data to specific diseases, risk factors,
conditions
In answering the following questions, imagine you want to
conduct a study on January 1, 2016. At this point, only
historical data would be available and that historical data
will be restricted to the codes defined in Table S2. The
focus in answering these questions should be around
whether particular code groups are available to conduct
the study.
13. With restricted collection of historic information to
codes for specific diseases, risk factors and conditions,
would it be possible to fully define the following
where fully defined means “as defined in the CPRD
study”?
a. Study population/denominator: (Select one of: Y,
N, n/a)
b. Primary exposure: (Select one of: Y, N, n/a)
c. Primary outcome: (Select one of: Y, N, n/a)
d. Important covariates/confounders—select N if the
answer for any of the covariates/confounders is
N: (Select one of: Y, N, n/a)
14. If N to any of Q13, could the study objectives have
been met, without major bias, if the definition of the
following were changed
a. Study population/denominator: (Select one of: Y,
N, n/a)
b. Primary exposure: (Select one of: Y, N, n/a)
c. Primary outcome: (Select one of: Y, N, n/a)
d. Important covariates/confounders—select N if the
answer for any of the covariates/confounders is
N: (Select one of: Y, N, n/a)
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115, with priority given to manuscripts with the most recent publica-
tion date, were systematically reviewed and included in the analysis
(Table S4).
3.1 | Study characteristics
An aggregate summary of the major characteristics of the included
manuscripts is shown in Table 1. Of the 100 studies analysed, 75
(75%) used CPRD primary care data alone, and 17 (17%) used CPRD
primary care data linked to other datasets, primarily Hospital Episode
Statistics Admitted Patient Care (HES APC) data. More than half of
the studies (52%) were published in the British Medical Journal
(BMJ). The majority focused on drug safety analysis (43%), disease
epidemiology (31%), or drug effectiveness (14%). Over a third of
studies (34%) researched circulatory system diseases. Neoplasms,
mental disorders, digestive system diseases, and endocrine‐ or
immunity‐related diseases were also covered in the top five
disease areas.
3.2 | Retrospective restriction according to disease
area
The hypothetical outcomes of repeating the included studies with ret-
rospective data collection restricted to specified diseases, risk factors,
conditions, and treatments are shown in Table 2.
The majority of studies (74%) were deemed unfeasible or com-
promised if conducted under the restricted data collection, often
with every area of study design affected. Of the affected studies,
69% (51/74) were unfeasible even with study design modification.
Among studies found to be unfeasible, even with study modification,
the majority (61%, [31/51]) were due to limitations on the primary
outcome; ie, data collected under the restriction did not include or
allow for a complete investigation of the primary outcome necessary
to answer the research question. Similarly, a large proportion of
studies that were compromised but could be modified to meet the
study objective required modification to the primary outcome
(87%, [20/23]).
3.3 | Retrospective restriction according to time
period
A marked proportion of studies were deemed either unfeasible or
compromised with restriction of retrospective data collection to a 6‐
(67%) or 12‐year period (22%).
Studies were largely compromised because of the impact of
restricted data collection over a limited period of either 6 (65%) or
12 years (18%). Misclassification leading to the introduction of bias
was a major limitation; of the studies affected by limited follow‐up
time, 79% (6 years, 51/65) and 83% (12 years, 15/18) would have
suffered from misclassification of exposure and/or outcome
(Table 3).
TABLE 1 Characteristics of included studies
Reason for inclusion %
Published in a high‐impact factor journal 79
Referenced in a UK clinical guidance document 17
Both 4
Year of publication %
2000 8
2001 5
2002 4
2003 5
2004 7
2005 6
2006 4
2007 8
2008 3
2009 6
2010 10
2011 3
2012 6
2013 11
2014 8
2015 2
Journal title %
British Medical Journal (BMJ) 52
Other 21
Journal of the American Medical Association (JAMA) 10
Lancet 8
International Journal of Epidemiology (IJE) 5
New England Journal of Medicine (NEJM) 3
Annals of Internal Medicine 1
Study type %
Adverse drug reaction/drug safety 43
Disease epidemiology 31
Drug effectiveness 14
Health/public health services research 8
Other 2
Drug utilisation 1
Methodological 1
Data source %
CPRD primary care data only 75
CPRD primary care linked data 17
Other nonlinked UK database 6
Other non‐UK database 2
Type of CPRD primary care linked data %
Any 17
HES admitted patient care 10
(Continues)
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Restriction by calendar period adversely affected studies to a
lesser, but still notable, extent compared with restricted follow‐up
time. Overall, 10% (2010 onwards) and 8% (2004 onwards) of studies
were affected by restricted calendar time, primarily because of expo-
sures, outcomes, or events of interest having occurred prior to that
point (Table 3).
3.4 | Restricted collection of sensitive data
Restricting the retrospective and prospective collection of sensitive
data limited the ability to conduct 10% of all studies included
(Table 4), primarily because of limitations on the study population
(80%, [8/10]). Of the affected studies, 50% were restricted because
they required legally restricted Read codes and 50% because they
required abortion or gender Read codes. In several cases, the study
population could not be defined because patients with potential immu-
nosuppression due to HIV and/or hepatitis could not be excluded.
Two studies remained unfeasible despite modifications (Table 4).
One focused on vaccine exposures during pregnancy and crucially
relied on information on pregnancy loss (termination/abortion/
miscarriage). The second focused on trends in sexually transmitted
infections, many of which are considered legally restricted terms.
Restricting collection of sensitive data had no impact (or was not
applicable) on any of the studies when considering the primary expo-
sure and important covariates used in the original research studies.
3.5 | Impact of full restriction
Individually, restricting retrospective data collection to specified dis-
ease areas, or to a period of 6 years, had the greatest impact on the
feasibility and overall internal validity of the studies reviewed.
When all restrictions were in place, over half (56%) of high‐impact
observational research studies were deemed unfeasible without the
introduction of major biases, and 35% of studies were deemed com-
promised. A total of 91% of studies were affected by the restrictions
proposed.
4 | DISCUSSION
4.1 | Summary
Large population health care databases that are used in public health
research exist worldwide.35-37 However, data quality and the extent
to which the database reflects the overall population can vary signifi-
cantly.38-40 Medical care in many countries may be funded altogether
or in part by medical insurers, meaning patient data are generally not
held centrally, are not continuous or representative, and cannot be
readily linked to other data sources. In contrast, the UK NHS primary
care EHR captures health data on over 90% of the UK population, cre-
ating a single continuous medical record for each patient over their
lifetime. It follows that UK primary care records, with their ability to
be linked to other data sets, are extensively used by regulators and
academic and pharmaceutical researchers worldwide.
The aim of the English care.data programme to collect data from all
general practices in England for the purposes of secondary uses
including research was laudable. Access to a larger patient dataset of
comparable research quality to those currently available from existing
UK research databases would further extend the utility of UK primary
care data, such as for research into rare diseases or events. The limita-
tions on the availability of primary care data for research proposed by
TABLE 1 (Continued)
Reason for inclusion %
ONS mortality 7
Deprivation 3
HES outpatient 2
Myocardial Ischaemia National Audit Project (MINAP) 2
Cancer registry 1
Other 1
Five most frequently studied disease areas %
Circulatory system diseases 34
Mental disorders 16
Neoplasms (ie, cancer related) 13
Digestive system diseases 12
Endocrine, nutritional, metabolic, and immunity disorders 11
Abbreviations: CPRD, Clinical Practice Research Datalink; HES, Hospital
Episode Statistics; ONS, Office for National Statistics.
TABLE 2 Impact on published studies due to retrospective data collection restricted to specified diseases only
Aspect of Study Affected by Restriction
Study
Population Exposure
Primary
Outcome
Important
Covariates
Study as
a Wholea
Total unfeasible or compromised studies, % (n = 100) 28 25 51 30 74
Studies with potential for modified design, % (n = 100) 12 7 20 15 23
Studies that could not be done, even with design changes, % (n = 100) 16 18 31 15 51
aStudies may have more than one reason for being unfeasible or compromised.
Key overall results highlighted in bold.
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the care.data programme therefore serve as a working model to under-
stand whether the benefits of increasing the size of the UK population
source are outweighed by curtailing the content and longitudinal
nature of the information within the EHR. By applying this model, this
study found that more than 90% of high‐impact studies conducted
using CPRD data would be compromised and greater than half would
be unfeasible to conduct with all data collection restrictions in place.
Retrospective collection restricted to prespecified disease areas
had a major impact on the number of research studies that could be
undertaken. Overall, 74% of all studies were affected by the restricted
database of which greater than half (51%) were not feasible even with
modifications. Loss of feasibility was primarily due to the inability to
identify primary outcomes of interest to the research question.
Research on musculoskeletal diseases, infectious diseases, and vaccine
efficacy would be severely limited, if not impossible under the pro-
posed restrictions. In a recent analysis, Vezyridis and Timmons identi-
fied the top keywords and disease areas associated with the output of
research publications conducted using UK primary care EHRs since
1995.6 Smoking, diabetes, cardiovascular disease, mental health, and
cancer were among the most frequent health areas researched and
appear among the proposed areas included in the present analysis. In
contrast, other top keywords and health areas including pregnancy,
fracture, gastrointestinal diseases, and vaccination would not be cap-
tured with the proposed restrictions.
Studies deemed unfeasible to conduct under the restriction
included an investigation published inThe Lancet confirming the safety
of the combined measles, mumps, and rubella vaccination.17 The
investigation followed the Wakefield study (1998), which raised con-
cerns over a link between the vaccine and the development of autism
in children and was instrumental in restoring confidence in the safety
of the vaccine.41 Without retrospective collection of vaccination data,
future surveillance of vaccine safety, uptake, and effectiveness would
be significantly compromised.
Longitudinal research studies rely on long‐term follow‐up to
ensure the accurate differentiation between newly diagnosed (inci-
dent) and established (prevalent) conditions. Sufficient follow‐up time
maintains statistical power when clinical outcome measures do not
occur for several years following risk factor exposure or intervention.
It is expected that constraining the collection of data to a specified
period would substantially affect exposure/outcome classification
and the feasibility of research on conditions with long lead time.
In line with this, more than two‐thirds of studies analysed were
deemed to be limited by reducing the retrospective data available to
a 6‐year period. Even with the extension of this period to 12 years,
almost a quarter of studies were still affected. Misclassification and
the consequent introduction of bias was a major limitation imposed
by the restricted database, with up to 79% of affected studies falling
into this category. This was particularly evident with exposures and
risk factors, which may be infrequently recorded or recorded only at
the point when a patient registers with their primary care provider,
such as smoking status, weight, and body mass index. Additionally,
populations that are used as controls in these studies often do not
have repeated or recent measures in their records. Such a restriction
would have significant implications for future development of accu-
rate risk algorithms and risk predictions tools. For example, an
TABLE 3 Impact on published studies due to restrictions on the time
period of data collectiona
Historical Data
Available From
01/01/2010
(6 y of Data)
Historical Data
Available From
01/01/2004
(12 y of Data)
Total unfeasible or compromised
studies according to year, %
(n = 100)
67 22
Compromised 55 14
Unfeasible 12 8
Studies compromised because of
restricted follow‐up, % (n = 100)
65 18
Bias introduced
(eg, misclassification)
51 15
Unable to measure exposure‐
outcome association
25 1
Cannot examine temporal trends 12 3
Study considered unfeasible 6 2
Studies compromised because of
restricted calendar time, %
(n = 100)
10 8
Exposure/outcome not available 1 0
Event of interest not available 9 8
Unfeasible for other reason 1 0
aSome studies are restricted by both follow‐up and calendar time and thus
included in both categories.
Key overall results highlighted in bold.
TABLE 4 Impact on published studies due to restrictions on collec-
tion of sensitive data
Aspect of Study Affected by
Restriction
Study
Population
Primary
Outcome Total
Total unfeasible or compromised
studies, % (n = 100)
8 2 10
Requiring legally restricted
Read codes
4 1 5
Requiring abortion or gender
Read codes
4 1 5
Studies with potential for modified
design, % (n = 100)
7 1 8
By changing definition of study
population
5 1 6
By using linked data from other
sources
2 0 2
Studies that could not be done, even
with design changes, % (n = 100)
1 1 2
Key overall results highlighted in bold.
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algorithm to predict the risk of blindness and amputation in individuals
with diabetes was developed using data from QResearch (and vali-
dated using CPRD data). This study used 16 years of patient data
and a range of clinical information to derive a reliable algorithm.42
Under the proposed longitudinal restrictions, the accuracy of the algo-
rithms and, ultimately, the usefulness of the predictor in clinical prac-
tice would be significantly reduced.
Up to one in 10 studies were limited in feasibility because of
restriction of data collection to a specific calendar time point, ie,
2010 onwards or 2004 onwards. Among the studies affected included
an investigation into the risk of stroke in individuals prescribed anti-
psychotic medication, prior to changes to safety recommendations in
2004, ie, prior to the hypothetical data collection restriction time
frames.43 Only making data available from a specified time point in
the recent past limits the ability to evaluate changes in clinical practice
and drug safety guidance in a timely manner.
Protecting patient anonymity is fundamental when conducting
research using sensitive information, such as studies on pregnancy,
abortion, gender, sexually transmitted infections, and HIV status. The
findings here show that one in 10 research studies would potentially
be affected by restricting the collection of such sensitive or legally
restricted data. Only two studies were deemed to be unfeasible
despite design changes, but these included an important public health
study establishing an increased risk of first venous thromboembolism
among pregnant women admitted to hospital, unrelated to delivery
admissions.44 Research studies investigating HIV or sexually transmit-
ted diseases would be significantly impaired by restrictions on sensi-
tive data. In addition, studies investigating cancer or immunity may
be subject to selection bias and effect modification if immunocompro-
mised individuals, such as those with HIV, could not reliably be
excluded from the analysis. The inability to carry out research on spe-
cific patient groups could have unintended consequences on patient
care if critical information cannot be taken into account.
4.2 | Strengths and limitations
This study has several key strengths including the application of a
robust review methodology. The review of study eligibility and subse-
quent assessment was conducted by two independent researchers, as
was the assessment of the impact of restrictions. A large sample of
studies was included across a broad range of disease areas. However,
studies published prior to 2000 were excluded. It should also be noted
that this study assessed the initial impact of restricting the collection
of retrospective data, which would reduce as the database matured.
4.3 | Comparison with existing literature
The accuracy and degree of completeness of health care data sources
is an essential consideration when conducting epidemiological
research and pharmacovigilance studies.38-40 A reduction in data com-
pleteness can reduce the applicability and usefulness of the data
source for pharmacovigilance and epidemiological studies.38-40 In
particular, data may become less suitable to support
pharmacovigilance studies that are dependent on a complete and con-
tinuous health record over time.39 It may therefore be preferable to
prioritise data quality over total patient numbers when considering
the value of health care database use for research purposes. This
study suggests that the value of complete and representative UK
EHR databases above larger, less representative databases available
in other countries may be significantly diminished when the scope of
collection is restricted.
4.4 | Implications for research and practice
Safeguarding the confidentiality and privacy of individuals when shar-
ing health data is paramount.45 It is crucial to gain public support for
responsible data sharing to generate an accurate source of informa-
tion on which decision makers depend. There have been several ini-
tiatives in the United Kingdom aimed at understanding public
attitudes to data sharing; it is hoped that the findings from this study
can be widely used to promote better understanding of the patient
and public health benefits of data sharing.46-48 Despite scepticism
towards government‐led health interventions from some sectors,
research has indicated that the majority of people do accept the
use of health data for public benefit.48 Furthermore, data show that
more than one in 30 UK citizens voluntarily take part in health
research studies.49
Costs of data collection and privacy concerns are key drivers of pol-
icy decisions. This study demonstrates that imposing restrictions on
information collected from EHRs may at face value allay privacy con-
cerns; however, this intervention may lead to inadvertent compromises
in patient and public safety. Moreover, limiting retrospective data col-
lection might save on data collection costs but prevent secondary use
of EHR data for epidemiological or pharmacoepidemiological studies
supporting essential drug safety and public health research.
The care.data programme did not progress to the stage of scaled
primary care data collection and was closed in 2016. Lessons learnt
from this programme can be used to inform the development of future
national initiatives in the United Kingdom and beyond seeking to man-
date collection of patient EHR. Experiences from the care.data pro-
gramme highlight the importance of stakeholder engagement,
garnering professional and public support and obtaining user input
into design, prior to implementing national EHR collection for second-
ary uses including research.
The findings from this study have applicability for policy and
health care decision makers globally who are seeking to develop
and implement systems to collect EHRs. It may be politically and
financially expedient to limit the scope of data collection. However,
it is prudent to also understand the potential impact of these deci-
sions on the ability to address national public health and drug safety
concerns in the future.
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